588 top medical experts on Hemolytic-Uremic Syndrome across 40 countries and 28 U.S. states, including 445 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Hemolytic-Uremic Syndrome: A syndrome that is associated with microvascular diseases of the kidney, such as renal cortical necrosis. It is characterized by hemolytic anemia (anemia, hemolytic); thrombocytopenia; and acute renal failure.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Uremia (1,460), Thrombotic Microangiopathies (1,286), Hemolytic Anemia (3,988) and Narrower Categories: Atypical Hemolytic Uremic Syndrome (2,251).
  4. Clinical Trials ClinicalTrials.gov : at least 48 including 3 Active, 17 Completed, 8 Recruiting
  5. Synonyms: Gasser's Syndrome


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Loirat, Chantal   Google Publications
    Pediatric Nephrology Department, University Hospital Robert Debré, Paris, France.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Antibodies, Monoclonal, Humanized; Escherichia coli Infections; Shiga-Toxigenic Escherichia coli; Thrombotic Microangiopathies; Autoantibodies
    Categories: Genetics; Therapeutic Use; Immunology; Therapy; Drug Therapy; Microbiology
    Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. (2013)
    Haemolytic uraemic syndrome. (2017)

  2. Trachtman, Howard   Pediatric Nephrology   ClinicalTrials.gov Google Publications
    Division of Nephrology, Department of Pediatrics, CTSI, NYU Langone Medical Center, 227 East 30th Street, Room #110, New York, NY 10016, USA. Electronic address: .
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 88.9/100
    Disclosed payments in 2021 from 7 biomedical companies, totalling $5,556.99, including $3,220 from  Roche Products Limited
    Subjects: Brain; Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Disease Outbreaks; Escherichia coli Infections
    Categories: Microbiology; Epidemiology; Etiology; Pathology; Complications; Immunology
    Renal and neurological involvement in typical Shiga toxin-associated HUS. (2012)
    HUS and TTP in Children. (2013)

  3. Tarr, Phillip I   Pediatric Gastroenterology   Google Publications
    Division of Gastroenterology, Hepatology, & Nutrition, Department of Pediatrics, Washington University in St Louis, School of Medicine, St Louis, MO.
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Relevant US NIH Grant Funding: $1,743,106 over the last 5 years
    Subjects: Escherichia coli Infections; Shiga-Toxigenic Escherichia coli; Escherichia coli O157; Anti-Bacterial Agents; Diarrhea
    Categories: Complications; Microbiology; Drug Therapy; Etiology; Isolation & Purification; Therapeutic Use
    Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. (2012)
    Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin-Producing Escherichia coli: A Systematic Review and Meta-analysis. (2017)

  4. Remuzzi, Giuseppe    ClinicalTrials.gov Google Publications
    IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Bergamo, Italy; Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Antibodies, Monoclonal, Humanized; Complement Activation; Escherichia coli Infections; Mutation; Complement C3a
    Categories: Genetics; Immunology; Pathology; Drug Effects; Therapeutic Use; Complications
    Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. (2013)
    Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. (2010)

  5. Nester, Carla M   Pediatric Nephrology   Google Publications
    Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA.  Top Hospital
    Physician  Highly Cited  Highly Published  Case Reports 
    Disclosed payments in 2021 from 3 biomedical companies, totalling $5,000, including $4,850 from  Novartis Pharmaceuticals Corporation
    Subjects: ADAM Proteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Kidney Transplantation; Plasminogen
    Categories: Genetics; Therapy; Administration & Dosage; Therapeutic Use; Blood; Deficiency
    Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. (2014)
    Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. (2011)

  6. Lifton, Richard P   Internal Medicine  Google Publications
    Department of Genetics, Howard Hughes Medical Institute and Yale Center for Mendelian Genomics, Yale University, New Haven, Connecticut. Top Hospital
    Physician 
    Disclosed payments in 2021 from 2 biomedical companies, totalling $25,000, including $25,000 from  Genentech, Inc.
    Subjects: Diacylglycerol Kinase; Genes, Recessive; Mutation
    Categories: Genetics; Etiology
    Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. (2013)
    Phenotypic expansion of DGKE-associated diseases. (2014)

  7. Cataland, Spero R   Hematology   Google Publications
    Internal Medicine, Ohio State University, Columbus, OH; Top Hospital
    Physician  Highly Published  Case Reports 
    Medical school: Ohio State University College of Medicine (MD, 1994)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 82.3/100
    Disclosed payments in 2021 from 12 biomedical companies, totalling $34,325.46, including $19,900 from  Takeda Pharmaceuticals U.S.A., Inc.
    Subjects: Antibodies, Monoclonal, Humanized; Complement Inactivating Agents; Purpura, Thrombotic Thrombocytopenic; Brain Diseases; Complement Activation
    Categories: Diagnosis; Therapeutic Use; Drug Therapy; Genetics; Therapy; Complications
    Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. (2014)
    How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. (2014)

  8. George, James N   Hematology & Oncology   Google Publications
    Department of Biostatistics and Epidemiology, College of Public Health, and Hematology-Oncology Section, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
    Physician  Highly Cited  Highly Published  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 52/100
    Subjects: Purpura, Thrombotic Thrombocytopenic; Plasma Exchange; Registries; Databases, Factual; Diarrhea
    Categories: Therapy; Chemically Induced; Epidemiology; Adverse Effects; Mortality; Diagnosis
    Drug-induced thrombotic microangiopathy: a systematic review of published reports. (2015)
    Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin. (2015)

  9. Quaggin, Susan E   Nephrology   Google Publications
    Division of Nephrology at the Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.  Top Hospital
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 86.9/100
    Disclosed payments in 2021 from 5 biomedical companies, totalling $11,280, including $5,740 from  F. Hoffmann-La Roche AG
    Subjects: Decision Support Techniques; Diacylglycerol Kinase; Genes, Recessive; Monitoring, Physiologic; Mutation
    Categories: Genetics; Etiology; Methods; Therapy
    DGKE and atypical HUS. (2013)
    Monitoring and modeling treatment of atypical hemolytic uremic syndrome. (2013)

  10. Griffin, Patricia M   Gastroenterology  Google Publications
    Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, GA.
    Physician  Highly Cited  Highly Published 
    Subjects: Escherichia coli Infections; Diarrhea; Escherichia coli O157; Population Surveillance; Shiga-Toxigenic Escherichia coli
    Categories: Epidemiology; Complications; Isolation & Purification; Microbiology; Adverse Effects; Etiology
    Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000-2010: epidemiologic features and comparison with E. coli O157 infections. (2013)
    Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. (2015)

  11. Kaplan, Bernard S   Pediatric Nephrology  Google Publications
    Division of Nephrology, Department of Pediatrics, The Childrens Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA, 19104, USA.
    Physician  Highly Published  Case Reports 
    Subjects: Pneumococcal Infections; Pseudomonas Infections; Sepsis; Acute Kidney Injury; Antibodies, Monoclonal, Humanized
    Categories: Diagnosis; Complications; Microbiology; Etiology; Genetics; Therapy
    Long-term outcomes of Shiga toxin hemolytic uremic syndrome. (2013)
    Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. (2013)

  12. Jones, Timothy F   Family Medicine  Google Publications
    Tennessee Department of Health, Nashville.
    Physician 
    Subjects: Escherichia coli Infections; Diarrhea; Shiga-Toxigenic Escherichia coli; Anti-Bacterial Agents; Centers for Disease Control and Prevention, U.S.
    Categories: Complications; Microbiology; Adverse Effects; Biosynthesis; Drug Effects; Drug Therapy
    Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. (2015)
    Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli. (2012)

  13. Andreoli, Sharon P   Pediatric Nephrology  Google Publications
    Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
    Physician  Clinical Trial 
    Subjects: Acute Kidney Injury; Oliguria; Diarrhea; Fluid Therapy; Hemorrhage
    Categories: Etiology; Therapy; Complications; Adverse Effects; Metabolism; Prevention & Control
    Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). (2019)
    Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. (2011)

  14. Thurman, Joshua M   Nephrology   Google Publications
    Department of Medicine, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, Colorado .
    Physician  Case Reports 
    Relevant US NIH Grant Funding: $1,556,591 over the last 5 years
    Medical school: University of Chicago, Pritzker School of Medicine (MD, 1997)
    Medicare Accepted
    Disclosed payments in 2021 from 2 biomedical companies, totalling $2,350, including $2,200 from  BioMarin Pharmaceutical Inc.
    Subjects: Complement C3a; Complement Pathway, Alternative; Kidney Glomerulus; Podocytes; Pregnancy Complications
    Categories: Drug Effects; Therapy; Metabolism; Pathology; Pharmacology
    Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. (2014)
    A Patient with Hemolytic Uremic Syndrome and Kidney Failure. (2018)

  15. Grabowski, Eric F   Pediatric Hematology-Oncology  Google Publications
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America. Top Hospital
    Physician 
    Relevant US NIH Grant Funding: $1,674,565 over the last 5 years
    Medical school: Mayo Medical School (MD, 1978)
    Medicare Accepted
    Disclosed payments in 2021 from 9 biomedical companies, totalling $449.55, including $449.55 from  Genentech, Inc.
    Subjects: Mannose-Binding Lectin; Antibodies, Monoclonal; Complement C3d; Escherichia coli Infections; Immunoglobulin G
    Categories: Metabolism; Drug Therapy; Therapeutic Use; Immunology; Toxicity
    Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. (2016)
    Platelet thrombus formation in eHUS is prevented by anti-MBL2. (2019)

  16. Rabinowitz, Peter M   Preventive Medicine/Occupational Environmental Medicine   Google Publications
    Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA 98195, USA. . Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72/100
    Subjects: Escherichia coli Infections; Escherichia coli O157; Anti-Bacterial Agents; Diarrhea; Shiga Toxin
    Categories: Microbiology; Complications; Genetics; Isolation & Purification; Etiology; Adverse Effects
    Contribution and Interaction of Shiga Toxin Genes to (2019)
    Strength of the association between antibiotic use and hemolytic uremic syndrome following Escherichia coli O157:H7 infection varies with case definition. (2018)

  17. Nataro, James P   Pediatric Infectious Diseases  Google Publications
    Physician  Highly Cited 
    Subjects: Disease Outbreaks; Escherichia coli; Shiga Toxin; Escherichia coli Infections; Genome, Bacterial
    Categories: Microbiology; Epidemiology; Genetics; Biosynthesis; Isolation & Purification; Metabolism
    Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. (2011)
    Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011. (2011)

  18. Prodhan, Parthak   Pediatric Critical Care Medicine   Google Publications
    Division of Nephrology, Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Childrens Hospital, Little Rock, AR; Division of Pediatric Cardiology/Pediatric Critical Care, University of Arkansas for Medical Sciences, Arkansas Childrens Hospital, Little Rock, AR.
    Physician 
    Medical school: Other (MD, 1990)
    Medicare Accepted
    Disclosed payments in 2021 from 2 biomedical companies, totalling $46.06, including $46.06 from  Abbott Laboratories
    Subjects: Brain Diseases; Heart Diseases; Hospital Mortality
    Categories: Epidemiology; Mortality
    Severe Acute Neurologic Involvement in Children With Hemolytic-Uremic Syndrome. (2021)
    Cardiac Manifestation among Children with Hemolytic Uremic Syndrome. (2021)

  19. Schnadower, David   Pediatric Emergency Medicine  Google Publications
    Division of Emergency Medicine, Cincinnati Childrens Hospital Medical Center, and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
    Physician  Review 
    Relevant US NIH Grant Funding: $1,743,106 over the last 5 years
    Subjects: Shiga-Toxigenic Escherichia coli; Clinical Decision Rules; Dehydration; Emergency Service, Hospital; Escherichia coli Infections
    Categories: Diagnosis; Complications; Methods; Microbiology; Pathogenicity; Therapy
    Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin-Producing Escherichia coli: A Systematic Review and Meta-analysis. (2017)
    Predicting Adverse Outcomes for Shiga Toxin-Producing Escherichia coli Infections in Emergency Departments. (2021)

  20. Conway, Edward M   Pediatrics  Google Publications
    UNIVERSITY OF BRITISH COLUMBIA CENTRE FOR BLOOD RESEARCH.
    Physician  Highly Cited 
    Subjects: Complement System Proteins; Thrombomodulin; Blood Coagulation; Complement Activation; Complement Factor H
    Categories: Genetics; Immunology; Deficiency; Administration & Dosage; Complications; Metabolism
    Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. (2010)
    Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. (2012)

Note:
  1. These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
  2. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);